trending Market Intelligence /marketintelligence/en/news-insights/trending/u7DgeNv5RiPTI76Pl_Y-Qg2 content esgSubNav
In This List

Sinopharm profit rises 1.42% YOY in H1

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sinopharm profit rises 1.42% YOY in H1

Shanghai-based Sinopharm Group Co. Ltd. said net profit attributable to shareholders rose 1.42% year over year to 650.83 million Chinese yuan for the six months ended June 30.

Diluted earnings per share totaled 1.52 yuan for the first half of 2019, compared to 1.50 yuan for the same period last year.

The Hong Kong-listed drugmaker also booked an operating profit of 8.30 billion yuan for the first six months of 2019, up from 7.17 billion yuan for the year-ago period.

Revenue for the six months increased to 201.67 billion yuan from 163.47 billion yuan a year earlier.

As of Aug. 23, US$1 was equivalent to 7.09 Chinese yuan.